METHODS FOR DIAGNOSING SOLID TUMORS

1 . A process for determining the signaling capability of bladder cancer cells, comprising:

Providing cells suspected of being bladder cancer cells, from an individual;

Identifying and selecting single cells that have an epithelial cell marker;

Determining aneuploidy of the cells;

Detecting and excluding cells that are undergoing apoptosis;

Contacting the cells with EGF;

Contacting the cells with a PI3kinase or MAP kinase pathway inhibitor; and

Determining the level of activatable elements in the single cells, comprising p-AKT and p-ERK.

2 . A process in accordance with claim 1 , further comprising administering a therapeutic agent to the individual based on the determination of the activatable elements of the single cells.

3 . A process in accordance with claim 1 , wherein the level of detection is less than 9 cells per 10,000,000.

4 . A process in accordance with claim 1 , wherein the step for determining if a cell is an epithelial cell uses reagents designed to detect EpCAM, Cytokeratin, CD45, estrogen receptor, HER2, CD44, vimentin, cadherin, or EGFR.

5 . A process in accordance with claim 1 , wherein the step for determining the aneuploidy of the cell uses a DNA cell content dye.

6 . A process in accordance with claim 1 , wherein the step for determining if a cell is undergoing apoptosis measures c-PARP, cleaved cytokeratin 18, cleaved caspase, cleaved caspase 3, cytochrome C, apoptosis inducing factor, MCL-1, BCL-2, BCL-XL, PUMA, NOXA, Bim, Bad, Bad, Bax, p53, c-myc proto-oncogene, APO-1/Fas/CD95, Annexin-V, 7-AAD, Amine Aqua, trypan blue, or propidium iodide.

7 . A process in accordance with claim 1 , further comprising analyzing the cells using a flow cytometer or mass spectrometer.

8 . A process for analyzing solid tumor cells circulating in whole blood, comprising:

Obtaining whole blood and enriching for circulting tumor cells (CTCs);

Determining and selecting each CTC that is an epithelial cell;

Determining if the CTC is malignant, as measured by aneuploidy;

Determining and excluding any CTC that is undergoing apoptosis;

Contacting the CTC with a modulator;

Contacting the CTC with a compound to interrupt signaling in the PI3Kinase and MAP kinase pathways; and

Detecting activatable elements by contacting the cells with EGF and detecting p-Akt and P-Erk.

9 . A process in accordance with claim 8 , further comprising administering a therapeutic agent to the individual based on the determination of the activatable elements of the single cells.

10 . A process in accordance with claim 8 , wherein the level of detection is less than 9 cells per 10,000,000.

11 . A process in accordance with claim 8 , wherein the step for determining if a cell is an epithelial cell uses reagents designed to detect EpCAM, Cytokeratin, CD45, estrogen receptor, HER2, CD44, vimentin, cadherin, or EGFR.

12 . A process in accordance with claim 8 , wherein the step for determining the aneuploidy of the cell uses a DNA cell content dye.

13 . A process in accordance with claim 8 , wherein the step for determining if a cell is undergoing apoptosis measures c-PARP, cleaved cytokeratin 18, cleaved caspase, cleaved caspase 3, cytochrome C, apoptosis inducing factor, MCL-1, BCL-2, BCL-XL, PUMA, NOXA, Bim, Bad, Bad, Bax, p53, c-myc proto-oncogene, APO-1/Fas/CD95, Annexin-V, 7-AAD, Amine Aqua, trypan blue, or propidium iodide.

14 . A process in accordance with claim 8 , further comprising analyzing the cells using a flow cytometer or mass spectrometer.

15 . A process for determining the signaling capability of biliary cancer cells, comprising:

Providing cells suspected of being biliary cancer cells, from an individual;

Identifying and selecting single cells that have an epithelial cell marker;

Determining aneuploidy of the cells;

Detecting and excluding cells that are undergoing apoptosis;

Contacting the cells with EGF;

Contacting the cells with a PI3kinase or MAP kinase pathway inhibitor; and

Determining the level of activatable elements in the single cells, comprising p-AKT and p-ERK.

16 . A process in accordance with claim 1 , further comprising administering a therapeutic agent to the individual based on the determination of the activatable elements of the single cells.

17 . A process in accordance with claim 1 , wherein the level of detection is less than 9 cells per 10,000,000.

18 . A process in accordance with claim 1 , wherein the step for determining if a cell is an epithelial cell uses reagents designed to detect EpCAM, Cytokeratin, CD45, estrogen receptor, HER2, CD44, vimentin, cadherin, or EGFR.

19 . A process in accordance with claim 1 , wherein the step for determining the aneuploidy of the cell uses a DNA cell content dye.

20 . A process in accordance with claim 1 , wherein the step for determining if a cell is undergoing apoptosis measures c-PARP, cleaved cytokeratin 18, cleaved caspase, cleaved caspase 3, cytochrome C, apoptosis inducing factor, MCL-1, BCL-2, BCL-XL, PUMA, NOXA, Bim, Bad, Bad, Bax, p53, c-myc proto-oncogene, APO-1/Fas/CD95, Annexin-V, 7-AAD, Amine Aqua, trypan blue, or propidium iodide.

21 . A process in accordance with claim 1 , further comprising analyzing the cells using a flow cytometer or mass spectrometer.

22 . A process for analyzing solid tumor cells circulating in whole blood, comprising:

Obtaining whole blood containing CTCs;

Selecting individual CTCs that are epithelial cells;

Determining if the CTC is malignant;

Excluding any CTC that is undergoing apoptosis; and

Detecting activatable elements in the MAP Kinase or P13 kinase pathways by contacting the cells with EGF and detecting activatable elements in the MAP Kinase or P13 kinase pathways.

23 . A kit for performing the processes according to claim 1 :

(a) binding elements for detecting one or more proteins or peptides; and

(c) modulator for stimulating a cell's signaling pathway.

24 . A kit for performing the processes according to claim 23 :

(a) wherein the binding elements detect p-AKT and p-ERK;

(b) wherein the modulator is EGF.